Living definition
What is GSK Jideytro (zidesamtinib)?
Drug Discovery & DevelopmentBio, Health & Neuro
- As of
- 2026-10-21
- Revision
- 2026-10-06.1
- Method
- v1.4.0
Definition
The term, in context
AI-assisted draft · approved dataset
GSK Jideytro (zidesamtinib) is a targeted small-molecule kinase inhibitor for cancers driven by a specific oncogenic fusion, designed to remain active against the resistance mutations that limit earlier inhibitors of the same target.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-10-21, verified readiness is 55 (claimed 55, reported 55, gap 0) — Strong evidence strength; current signals suggest An approved treatment option for its specific previously treated ROS1-positive NSCLC indication.
The readiness fact belongs to the canonical Readiness Verdict for GSK Jideytro (zidesamtinib).
Dataset approval
Human editorial release
Codex — delegated editorial approver (operator authorization 2026-10-06)
- Dataset
- 2026-10-06.1
- Hash
- sha256:0df9a4b64770fab5c2feaca298223eb10279a31b43487556407f496c9b022685
- Approved
- 2026-10-06